Skip to main content
Baotou Dongbao Bio-Tech Co.,Ltd. logo

Baotou Dongbao Bio-Tech Co.,Ltd. — Investor Relations & Filings

Ticker · 300239 ISIN · CNE100001583 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,072 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300239

About Baotou Dongbao Bio-Tech Co.,Ltd.

https://www.dongbaoshengwu.com

Baotou Dongbao Bio-Tech Co.,Ltd. specializes in the research, development, production, and distribution of gelatin and collagen-based products. The company’s primary portfolio includes medicinal gelatin, edible gelatin, and high-purity collagen peptides. These products serve diverse applications across the pharmaceutical, food, and health supplement sectors. Specifically, its medicinal gelatin is utilized in the manufacturing of hard and soft capsules, while its edible gelatin is a key ingredient in confectionery and dairy products. The company also focuses on hydrolyzed collagen for use in functional foods and cosmetic formulations. By leveraging advanced biotechnology and large-scale manufacturing capabilities, the firm provides specialized solutions for protein-based ingredients, emphasizing quality control and technical innovation in the field of animal-derived protein processing.

Recent filings

Filing Released Lang Actions
关于参加2026年内蒙古辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 80% confidence The document is an announcement about the company’s participation in an investor online reception day event, without any actual financial statements, results, or regulatory form filings. It does not present financial data (so not an earnings release or interim report), nor is it a proxy, dividend notice, or governance charter. It is a general corporate/regulatory announcement aimed at investors, which falls under the fallback category “Regulatory Filings” (RNS).
2026-05-22 Chinese
关于“东宝转债”转股价格调整的公告
Capital/Financing Update Classification · 85% confidence The document is an official Shenzhen Stock Exchange announcement by Baotou Dongbao Bio regarding the adjustment of the conversion price for its outstanding convertible bonds (“东宝转债”). It details the bond code, original and adjusted conversion prices, effective dates, regulatory approval, and formulas for price adjustments tied to dividend distributions. This is clearly a financing/instrument update rather than an earnings report, management discussion, or annual/quarterly financial statement. It fits the Capital/Financing Update category.
2026-05-18 Chinese
关于实施权益分派期间“东宝转债”暂停转股的提示性公告
Capital/Financing Update Classification · 85% confidence The document is a short “提示性公告” informing bondholders of a convertible bond (code 123214) about the temporary suspension and later resumption of conversion rights around the equity distribution date, including conversion price adjustment formulas. It is not an annual or interim report, earnings release, legal proceeding, or director dealing notice. Instead, it provides updates on an existing financing instrument and its impact on capital structure. Therefore it classifies as a Capital/Financing Update (CAP).
2026-05-14 Chinese
第十届董事会第二次会议决议公告
Board/Management Information Classification · 73% confidence The document is an official announcement of the Board of Directors’ meeting resolutions (第十届董事会第二次会议决议公告) detailing the date, attendance, agenda, voting results and approved resolution on convertible bond conversion price. This is a corporate board/management information disclosure rather than an earnings release, financial report, or change in shareholding. It fits the Board/Management Information category.
2026-05-11 Chinese
包头东宝生物技术股份有限公司关于不向下修正“东宝转债”转股价格的公告
Capital/Financing Update Classification · 85% confidence The document is an announcement by Baotou Dongbao Bio-technology Co., Ltd. regarding its convertible bonds (“東寶轉債”) and, specifically, the board’s decision not to downward adjust the conversion price. It provides details on the bond issuance, listing, conversion terms, downward adjustment triggers, and the board resolution. This is not a financial report (e.g., interim or annual report) nor a regulatory filing of a different nature; it is a corporate notice related to the company’s capital structure and financing instrument. Therefore, it falls under “Capital/Financing Update” (CAP).
2026-05-11 Chinese
第九届董事会第十六次会议决议公告
Regulatory Filings Classification · 80% confidence The document is a Chinese board meeting resolution announcement (“第九届董事会第十六次会议决议公告”) describing the convocation, attendance, and resolutions (including approving the Q1 2026 report) of a Board of Directors meeting. It is not the full quarterly report itself (IR), nor a simple announcement of report publication (RPA) or management discussion (MDA), nor is it announcing changes in board composition (MANG). It falls under general regulatory announcements that do not fit a more specific category, so it should be classified as a Regulatory Filing (RNS).
2026-04-23 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.